Serum IL-33 level is associated with auto-antibodies but not with clinical response to biologic agents in rheumatoid arthritis

Serum IL-33 level is associated with auto-antibodies but not with clinical response to biologic agents in rheumatoid arthritis

Trial registration Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis (ROC), registered 22 October 2009, NCT01000441

Bibliographic Details
Main Authors: Elodie Rivière, Jérémie Sellam, Juliette Pascaud, Philippe Ravaud, Jacques-Eric Gottenberg, Xavier Mariette
Format: Article
Language:English
Published: BMC 2018-06-01
Series:Arthritis Research & Therapy
Subjects:
Interleukin 33
Personalized medicine
Rheumatoid arthritis
Biologic agents
Online Access:http://link.springer.com/article/10.1186/s13075-018-1628-6

Internet

http://link.springer.com/article/10.1186/s13075-018-1628-6

Similar Items